18 / 27
…and they may impact in survival…
– Not all patients receiving 1L Placebo crossed to Lenvatinib upon
progression in the SELECT trial:
12% never crossed due to rapid
disease deterioration
– RPFST estimated OS in 1L Placebo arm topped at
19.1 months
Guo M, et al. ECCO-ESMO Congress 2015; abstract no. 2805
Median (months) (95% CI)
Lenvatinib
NE (30.9–NE)
Placebo
19.1 (14.3–NE)
P=0.005 (adjusted)
Data cut-off date: 15 Jun 2014